Lopinavir And Ritonavir has 88 known drug interactions based on U.S. FDA drug labeling data. Of these, 18 are contraindicated combinations that should be avoided entirely. 13 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Abemaciclib, Alfuzosin, Apalutamide. Patients taking Lopinavir And Ritonavir should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 88
- Contraindicated
- 18
- Major
- 13
- Moderate
- 19
- Minor
- 2
Contraindicated (18)
- Lopinavir And Ritonavir + Abemaciclib— Anticancer Agents: abemaciclib, apalutamide, encorafenib, ibrutinib, ivosidenib, dasatinib, neratinib, nilotinib, veneto…
- Lopinavir And Ritonavir + Alfuzosin— Other Agents Alpha 1-Adrenoreceptor Antagonist: alfuzosin ↑ alfuzosin Contraindicated due to potential hypotension [see …
- Lopinavir And Ritonavir + Apalutamide— Anticancer Agents: abemaciclib, apalutamide, encorafenib, ibrutinib, ivosidenib, dasatinib, neratinib, nilotinib, veneto…
- Lopinavir And Ritonavir + Atorvastatin— Lipid-modifying agents HMG-CoA Reductase Inhibitors: lovastatin simvastatin atorvastatin rosuvastatin Microsomal triglyc…
- Lopinavir And Ritonavir + Colchicine Tablets 0.5 Mg— Strong CYP3A4 inhibitor causing significant increases in colchicine plasma levels.
- Lopinavir And Ritonavir + Dasatinib— Anticancer Agents: abemaciclib, apalutamide, encorafenib, ibrutinib, ivosidenib, dasatinib, neratinib, nilotinib, veneto…
- Lopinavir And Ritonavir + Elbasvir— Hepatitis C direct acting antiviral: elbasvir/grazoprevir ↑ elbasvir/grazoprevir Contraindicated due to increased risk o…
- Lopinavir And Ritonavir + Encorafenib— Anticancer Agents: abemaciclib, apalutamide, encorafenib, ibrutinib, ivosidenib, dasatinib, neratinib, nilotinib, veneto…
- Lopinavir And Ritonavir + Grazoprevir— Hepatitis C direct acting antiviral: elbasvir/grazoprevir ↑ elbasvir/grazoprevir Contraindicated due to increased risk o…
- Lopinavir And Ritonavir + Ibrutinib— Anticancer Agents: abemaciclib, apalutamide, encorafenib, ibrutinib, ivosidenib, dasatinib, neratinib, nilotinib, veneto…
- Lopinavir And Ritonavir + Ivosidenib— Anticancer Agents: abemaciclib, apalutamide, encorafenib, ibrutinib, ivosidenib, dasatinib, neratinib, nilotinib, veneto…
- Lopinavir And Ritonavir + Lovastatin— Lipid-modifying agents HMG-CoA Reductase Inhibitors: lovastatin simvastatin atorvastatin rosuvastatin Microsomal triglyc…
- Lopinavir And Ritonavir + Midazolam— Sedative/Hypnotics: triazolam, orally administered midazolam ↑ triazolam ↑ midazolam Contraindicated due to potential fo…
- Lopinavir And Ritonavir + Neratinib— Anticancer Agents: abemaciclib, apalutamide, encorafenib, ibrutinib, ivosidenib, dasatinib, neratinib, nilotinib, veneto…
- Lopinavir And Ritonavir + Nilotinib— Anticancer Agents: abemaciclib, apalutamide, encorafenib, ibrutinib, ivosidenib, dasatinib, neratinib, nilotinib, veneto…
- Lopinavir And Ritonavir + Rosuvastatin— Lipid-modifying agents HMG-CoA Reductase Inhibitors: lovastatin simvastatin atorvastatin rosuvastatin Microsomal triglyc…
- Lopinavir And Ritonavir + Simvastatin— Lipid-modifying agents HMG-CoA Reductase Inhibitors: lovastatin simvastatin atorvastatin rosuvastatin Microsomal triglyc…
- Lopinavir And Ritonavir + Triazolam— Sedative/Hypnotics: triazolam, orally administered midazolam ↑ triazolam ↑ midazolam Contraindicated due to potential fo…
Major (13)
- Lopinavir And Ritonavir + Atorvaliq— Significantly increases atorvastatin plasma levels. Consider risk/benefit of concomitant use.
- Lopinavir And Ritonavir + Atorvastatin Calcium— Significantly increases atorvastatin plasma levels. Consider risk/benefit of concomitant use.
- Lopinavir And Ritonavir + Erlotinib— Strong CYP3A4 inhibitor increases erlotinib exposure, raising risk of exposure-related toxicity. Avoid co-administration…
- Lopinavir And Ritonavir + Erlotinib Hydrochloride— Strong CYP3A4 inhibitor that increases erlotinib exposure and risk of exposure-related toxicity. Avoid co-administration…
- Lopinavir And Ritonavir + Fosamprenavir— Co-administration results in decreased amprenavir and lopinavir concentrations with increased rate of adverse reactions.…
- Lopinavir And Ritonavir + Lamivudine And Tenofovir Disoproxil Fumarate— Increases tenofovir concentrations. Monitor for tenofovir-associated adverse reactions; discontinue if adverse reactions…
- Lopinavir And Ritonavir + Lamotrigine— Lopinavir/ritonavir decreases lamotrigine concentration by approximately 50%, requiring dose adjustment.
- Lopinavir And Ritonavir + Norethindrone And Ethinyl Estradiol— HIV protease inhibitor that may significantly decrease plasma concentrations of norethindrone and ethinyl estradiol, pot…
- Lopinavir And Ritonavir + Norgestimate And Ethinyl Estradiol— HIV protease inhibitor combination that decreases plasma concentrations of estrogen and/or progestin, potentially dimini…
- Lopinavir And Ritonavir + Palbociclib— Strong CYP3A inhibitor. Avoid concomitant use or reduce palbociclib dose if unavoidable.
- Lopinavir And Ritonavir + Paricalcitol— Strong CYP3A inhibitor increases paricalcitol exposure. Dose adjustment may be necessary; monitor intact PTH and serum c…
- Lopinavir And Ritonavir + Rosuvastatin Calcium— Combination increases rosuvastatin exposure up to 3-fold. Limit rosuvastatin dose to 10 mg once daily.
- Lopinavir And Ritonavir + Tenofovir Disoproxil Fumarate— Coadministration increases tenofovir concentrations. Monitor for evidence of tenofovir toxicity.
Moderate (19)
- Lopinavir And Ritonavir + Amlodipine And Atorvastatin— Consider risk/benefit of concomitant use with atorvastatin due to increased myopathy risk.
- Lopinavir And Ritonavir + Desogestrel And Ethinyl Estradiol And Ethinyl Estradiol— HIV protease inhibitor that decreases plasma concentrations of estrogen and/or progestin.
- Lopinavir And Ritonavir + Dolutegravir Sodium— Coadministration with etravirine mitigates etravirine-induced reduction of dolutegravir plasma concentrations.
- Lopinavir And Ritonavir + Efavirenz— Efavirenz decreases lopinavir concentrations. Once daily dosing not recommended when coadministered.
- Lopinavir And Ritonavir + Efavirenz, Emtricitabine And Tenofovir Disoproxil Fumarate— Coadministration increases tenofovir concentrations. Monitor for evidence of tenofovir toxicity.
- Lopinavir And Ritonavir + Emtricitabine And Tenofovir Disoproxil Fumarate— Lopinavir/ritonavir increases tenofovir concentrations. Monitor for evidence of tenofovir toxicity.
- Lopinavir And Ritonavir + Emtricitabine/Tdf— Coadministration may alter lopinavir/ritonavir and tenofovir concentrations. Monitoring recommended.
- Lopinavir And Ritonavir + Etonogestrel— HIV protease inhibitor combination that may decrease plasma concentrations of etonogestrel.
- Lopinavir And Ritonavir + Fostamatinib— Kinase Inhibitors: fostamatinib (also see anticancer agents above) ↑ fostamatinib metabolite R406 Monitor for toxicities…
- Lopinavir And Ritonavir + Indinavir— Co-administration increases indinavir concentrations. Indinavir dose should be decreased to 600 mg twice daily.
- Lopinavir And Ritonavir + Isavuconazonium Sulfate— 96% increase in isavuconazole exposure when coadministered. Also causes decreased exposure of lopinavir and ritonavir wi…
- Lopinavir And Ritonavir + Lamotrigine Chewable Dispersible— Decreased lamotrigine concentration approximately 50%.
- Lopinavir And Ritonavir + Lamotrigine Extended-Release— Decreases lamotrigine concentration approximately 50%.
- Lopinavir And Ritonavir + Levonorgestrel And Ethinyl Estradiol And Ferrous Fumarate— HIV protease inhibitor combination that may decrease plasma concentrations of estrogen and/or progestin.
- Lopinavir And Ritonavir + Nelfinavir— Co-administration increases nelfinavir and M8 metabolite concentrations while decreasing lopinavir. KALETRA once daily w…
- Lopinavir And Ritonavir + Nevirapine— Dose adjustment to 500/125 mg tablets or 533/133 mg oral solution twice daily recommended due to decreased lopinavir exp…
- Lopinavir And Ritonavir + Norelgestromin And Ethinyl Estradiol— HIV protease inhibitor that may decrease plasma concentrations of estrogen and/or progestin.
- Lopinavir And Ritonavir + Norethindrone— Significant decrease in systemic concentrations of norethindrone may occur.
- Lopinavir And Ritonavir + Norgestrel And Ethinyl Estradiol— HIV protease inhibitor may significantly decrease plasma concentrations of estrogen and/or progestin.
Minor (2)
- Lopinavir And Ritonavir + Eltrombopag— No dose adjustment recommended when coadministered with eltrombopag.
- Lopinavir And Ritonavir + Eltrombopag Olamine— No dose adjustment recommended when coadministered with eltrombopag.